Article Versions Notes

Shin D, Ha S, O JH, Rhew Sa, Yoon CE, Kwon HJ, Moon HW, Park YH, Park SY, Park C, et al. A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [¹⁷⁷Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial. Cancers. 2022; 14(24):6225. https://doi.org/10.3390/cancers14246225

Shin, Dongho, Seunggyun Ha, Joo Hyun O, Seung ah Rhew, Chang Eil Yoon, Hyeok Jae Kwon, Hyong Woo Moon, Yong Hyun Park, Sonya Youngju Park, Chansoo Park, and et al. 2022. "A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [¹⁷⁷Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial" Cancers 14, no. 24: 6225. https://doi.org/10.3390/cancers14246225

Shin, D., Ha, S., O, J. H., Rhew, S. a., Yoon, C. E., Kwon, H. J., Moon, H. W., Park, Y. H., Park, S. Y., Park, C., Chi, D. Y., Yoo, I. R., & Lee, J. Y. (2022). A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [¹⁷⁷Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial. Cancers, 14(24), 6225. https://doi.org/10.3390/cancers14246225